Search

Displaying results 381 - 390 of 536 in total
  1. Drug

    Gaboxadol

    go.drugbank.com/drugs/DB06554
    Investigational

    Development of Gaboxadol was stopped in March 2007 after concerns regarding safety and efficacy. It acts on the GABA system, but in a seemingly different way from benzodiazepines and other sedatives.

  2. Target

    Mitochondrial ATP synthase F1 domain

    go.drugbank.com/bio_entities/BE0010209
    TargetEnzymeHumans

    Part of the complex F(0) domain (PubMed:37244256). … ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256).

    Polypeptides: ATP synthase F(1) complex subunit alpha, mitochondrial, ATP synthase F(1) complex subunit beta, mitochondrial
  3. Drug

    Tepotinib

    go.drugbank.com/drugs/DB15133
    ApprovedInvestigational

    Tepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with _MET_ alterations, and was subsequently granted accelerated approval by the US FDA in February

  4. Target

    Mitochondrial amidoxime reducing component 2

    go.drugbank.com/bio_entities/BE0017987
    EnzymeHumans

    Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles (PubMed:21029045, PubMed:24423752). As a component of prodrug-converting system, reduc...

    Synonyms: MARC2
  5. Target

    Mitochondrial amidoxime-reducing component 1

    go.drugbank.com/bio_entities/BE0015448
    EnzymeHumans

    Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles (PubMed:19053771, PubMed:21029045, PubMed:30397129). As a component of prodrug-convert...

    Synonyms: MARC1
  6. Drug

    Zavegepant

    go.drugbank.com/drugs/DB15688
    ApprovedInvestigational

    [A258190,A258195] In March 2023, the FDA approved the use of zavegepant nasal spray for the acute treatment of migraine with or without aura in adults.

  7. Drug

    Empagliflozin

    go.drugbank.com/drugs/DB09038
    ApprovedInvestigational

    Empagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart

  8. Drug

    Acetaminophen

    go.drugbank.com/drugs/DB00316
    ApprovedInvestigational

    Acetaminophen (paracetamol), also commonly known as Tylenol, is the most commonly taken analgesic worldwide and is recommended as first-line therapy in pain conditions by the World Health Organization (WHO). It is also used for its antip...

    Mixtures: PARACETAMOLO E CODEINA DOC GENERICI, PARACETAMOL AL COMPProducts: PARACETAMOLO MARCO VITI, PARACETAMOLO DOC GENERICI
  9. Drug

    Methyl salicylate

    go.drugbank.com/drugs/DB09543
    ApprovedInvestigationalVet approved

    Methyl salicylate (oil of wintergreen or wintergreen oil) is an organic ester naturally produced by many species of plants, particularly wintergreens. The compound was first extracted and isolated from plant species Gaultheria procumbens...

    Mixtures: Marcs Original, Marcs Blue MintCategories: Complex Mixtures
  10. Drug

    Durvalumab

    go.drugbank.com/drugs/DB11714
    ApprovedInvestigational

    [A192789,L12627] On March 27, 2020, durvalumab was approved by the FDA for use in combination with [etoposide] and either [carboplatin] or [cisplatin] as first-line treatment of patients with extensive-stage